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1  | INTRODUC TION
Irritable bowel syndrome (IBS) is characterized by recurrent ab‐
dominal pain associated with abnormal bowel habits. It is one of the 
most common functional gastrointestinal (GI) disorders, with an esti‐
mated worldwide prevalence of 2%‐11%, depending on country and 
diagnostic criteria used.1 IBS has a detrimental effect on the quality 
of life,2‒5 frequently results in work absenteeism,4 and produces high 
healthcare costs.4,6
IBS patients are currently diagnosed based on the Rome criteria7,8 
(with Rome IV being the latest version), consisting of a combination 
of symptom‐based criteria, which sometimes are supplemented by 
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Background: In a previous clinical sample of IBS patients, subgroups characterized by 
profiles of GI and non‐GI symptoms were identified. We aimed to replicate these 
subgroups and symptom associations in participants fulfilling IBS diagnostic criteria 
from a population‐based study and relate them to healthcare utilization.
Methods:	An	Internet‐based	health	survey	was	completed	by	general	population	adults	
from	United	States,	Canada,	and	UK.	Respondents	fulfilling	IBS	diagnosis	(Rome	III	and	
IV) were analyzed for latent subgroups using Gaussian mixture model analysis. Symptom
measures were derived from validated questionnaires: IBS‐related GI symptoms (Rome
IV),	extraintestinal	somatic	symptoms	(PHQ‐12),	and	psychological	symptoms	(SF‐8).
Key Results:	 A	 total	 of	 637	 respondents	 fulfilled	 Rome	 III	 criteria	 (average	 age
46 years, range 18‐87, 66% females) and 341 Rome IV criteria (average age 44, range
18‐77, 64% female) for IBS. Seven subgroups were identified in the Rome III cohort,
characterized by profiles of GI symptoms (constipation‐related, diarrhea‐related, and
mixed, respectively), and further distinguished by the presence or absence of non‐GI
comorbidities. The Rome IV cohort showed five similar but less distinct subgroups
with a preponderance of mixed symptom profiles. Higher severity of non‐GI comor‐
bidities was associated with more frequent healthcare visits and medication usage.
Conclusions and Inferences: In line with previous findings in a clinical IBS cohort, we
were able to identify population‐based subgroups characterized by a combination of
GI symptoms with the additional distinction made by varying severity of non‐GI
symptoms and with differences in healthcare utilization.
K E Y W O R D S
general population, irritable bowel syndrome, latent profile analysis, mixture model, 
subgrouping
diagnostic tests which must show no abnormal findings.8 The Rome 
IV criteria require recurring abdominal pain for at least one day per 
week during the last three months, which is associated with a change 
in form or frequency of stools and related to defecation.8	Apart	from	
abdominal pain and altered bowel habits, patients frequently display 
a variety of other GI symptoms, such as bloating, urgency, and ab‐
dominal	distention.	Additionally,	 extraintestinal	 somatic	 symptoms	
such as back and joint pain, headaches, sleep disturbances,9 as well 
as psychological symptoms, especially anxiety and depression,9,10 
are very common. While not all of these symptoms are present in all 
patients, those that are present are of high relevance for the overall 
disease burden of the respective patients and are important for indi‐
vidual treatment decisions.11 IBS presents as a very heterogeneous 
disorder and is therefore currently stratified into four different sub‐
types based on the Rome criteria7,8: IBS with constipation (IBS‐C), 
IBS	with	diarrhea	(IBS‐D),	IBS	with	mixed	bowel	habits	(IBS‐M),	and	
unclassified	IBS	(IBS‐U).	While	the	recently	updated	diagnostic	cri‐
teria (from Rome III to Rome IV) are considered to be stricter, as 
they require the presence of abdominal pain (not discomfort) and 
higher symptom frequency for IBS diagnosis, they have not included 
substantial changes to the subtyping strategy. This subtyping strat‐
egy is based solely on predominant stool consistency and does not 
take into account other symptoms for classification, despite their 
relevance for treatment strategies and outcome for the individual 
patients.11 It is currently not clear what consequences the updated 
diagnostic criteria have on the characteristics of the IBS cohort.
While there is a variety of different treatment options available 
for IBS patients, it is challenging to identify the optimal strategy for 
the	individual.	As	GI	symptoms	other	than	stool	consistency,	as	well	
as many non‐GI symptoms, have shown to be of relevance for opti‐
mized individual treatment decisions,11‒14 a need for a more compre‐
hensive stratification approach of patients with IBS remains.
It has also been shown that the healthcare needs of IBS patients 
not only are associated with the severity of GI symptoms, but are 
also influenced by extraintestinal and psychological symptoms.15,16 
Therefore, in an era of rapidly rising healthcare costs, there is a need 
for practical methods to quickly and precisely identify the individual 
patients’	treatment	needs.
Aiming	 to	 improve	 the	 current	 subtyping	 options,	 our	 group	
has previously explored methods of stratifying a clinical cohort of 
IBS patients diagnosed with Rome III criteria, based on combina‐
tions of relevant gastrointestinal somatic, extraintestinal somatic 
and psychological symptoms utilizing advanced statistical tech‐
niques.17 The resulting subgroups were predominantly charac‐
terized by specific profiles of GI symptoms (constipation‐related, 
diarrhea‐related, and mixed), but further characterized by the 
presence or absence of a profile of extraintestinal comorbidities, 
resulting in a six‐subgroup solution: (I) constipation with low co‐
morbidities, (II) constipation with high comorbidities, (III) diarrhea 
with low comorbidities, (IV) diarrhea and pain with high comor‐
bidities, (V) mixed GI symptoms with high comorbidities, and (VI) 
a mix of symptoms with overall mild severity. These subgroups 
were identified in healthcare consulters recruited at an outpatient 
clinic, but it is known that to some extent patients differ from indi‐
viduals suffering from IBS symptoms without seeking health care 
(nonconsulters) with regards to illness behavior and coping strate‐
gies,18 and also psychological distress.19 It is unclear if the six sub‐
groups we identified in a clinical cohort also apply to individuals 
meeting Rome criteria for IBS in the general population.
In this study, the aim was to validate our previous findings by 
reproducing these subgroups in a population‐based cohort and to 
compare symptom associations present in respondents fulfilling 
Rome III criteria for IBS7 with those present in respondents ful‐
filling Rome IV criteria for IBS.8 Furthermore, we hypothesized a 
higher frequency of healthcare utilization in groups with comorbid 
non‐GI symptoms and aimed to compare the frequency of health‐
care utilization between subgroups.
2  | MATERIAL S AND METHODS
2.1 | The study cohort
An	 Internet‐based	 health	 survey	was	 completed	 by	 6300	 general	
population	 adults	 from	 the	 United	 States,	 Canada,	 and	 UK	 (2100	
from each country). The respondents fulfilling IBS diagnosis (Rome 
IV8 and III7) were analyzed for latent subgroups based on symptom 
measures derived from validated questionnaires: IBS‐related GI 
symptoms (Rome IV8),	extraintestinal	somatic	symptoms	(PHQ‐1220), 
and psychological symptoms (SF‐821).
2.2 | Questionnaire distribution and completion
To collect the data used in this study, a global market survey com‐
pany	(Qualtrics	Inc	(Provo,	Utah,	United	States))	was	assigned	with	
the distribution of the study questionnaire to a nationally repre‐
sentative general population sample of adults from three English‐
speaking	 countries:	 United	 States,	 Canada,	 and	 United	 Kingdom.	
Key Points
• IBS is a heterogeneous disorder. In a clinical sample of
IBS patients (Rome III), subgroups defined by specific
profiles of GI and non‐GI symptom severity were previ‐
ously identified. We aimed to replicate these subgroups
in a population‐based study.
• In participants fulfilling Rome III and Rome IV diagnostic 
criteria for IBS, the subgroups based on a combination
of GI and non‐GI symptom profiles could largely be rep‐
licated. Groups with more severe non‐GI symptoms re‐
ported higher healthcare utilization.
• This subgrouping approach could facilitate the identifi‐
cation of individual treatment needs and predict health‐
care consumption in IBS.
To	ensure	that	the	proportion	of	sex	(50:50),	age‐groups	(40%	aged	
19‐39,	 40%	 aged	 40‐64%,	 and	 20%	 aged	 65	 and	 older),	 and	 edu‐
cation level (maximum 30% with more than sixteen years of formal 
education) was equal across the countries, quota‐based sampling 
was conducted for the recruitment of participants. The individuals 
recruited had registered to participate in surveys, such as opinion 
polls and health studies. Suitable subjects were invited to partici‐
pate in a “health survey,” and to avoid selection bias, no information 
indicating that the focus of the study was in assessing GI symptoms 
was	given.	All	participants	read	and	signed	an	electronic	online	con‐
sent form to accept study enrollment and then completed the sur‐
vey. Several quality assurance methods were built into the survey to 
minimize bias and poor quality reporting. These quality assurance 
methods allowed only one response from each computer device and 
excluded participants who did not pass attention test questions or 
were inconsistent in their responses to the three GI diagnostic ques‐
tions that were presented twice in the survey with the aim of testing 
consistency of symptom reporting. For more detailed information 
about this survey, please see Ref.22‒24
2.3 | Questionnaires
The questions completed by the study participants consisted of vali‐
dated questionnaires designed to diagnose and measure symptom 
severity of IBS as well as associated factors such as somatic symp‐
toms and quality of life. The study also contained questions enquir‐
ing about age, gender, and ethnicity of the participants. Details are 
described below.
2.3.1 | GI symptoms: Rome diagnostic 
questionnaires
The survey contained the complete Rome IV diagnostic question‐
naire8 as well as those questions from the Rome III questionnaire7 
required for IBS diagnosis. The Rome IV questionnaire presents par‐
ticipants with 26‐86 questions (depending on skip patterns used if 
a participant does not have specific symptoms) asking for the fre‐
quency and/or severity of FGID‐related symptoms. Based on these 
questionnaires, we determined which participants fulfilled the Rome 
III and Rome IV diagnostic criteria for IBS,7,8 respectively (termed 
Rome III‐ or Rome IV‐positive in the course of this text). To repre‐
sent the frequency and/or severity of IBS‐related GI symptoms in 
our mixture model analysis, we have used the following questions 
from the Rome IV questionnaire: “pain frequency” (question 40), 
“pain	after	meal”	 (question	45),	“pain	severity”	 (question	46),	“hard	
stools”	 (question	 49),	 “infrequent	 stools”	 (question	 51),	 “straining”	
(question	52),	“incomplete	bowel	movements”	(question	53),	“loose	
stools”	 (question	 59),	 “urgency”	 (question	 63),	 and	 “bloating	 fre‐
quency”	(question	65).	Pain	and	bloating	frequency	are	determined	
using a scale with 9 response alternatives, ranging from “never” to 
“multiple times per day or all the time,” whereas the other questions 
used an 11‐grade scale, ranging from “never (0%)” to “always (100%).” 
These questions were selected to match the GI questions used in the 
previous study17 as closely as possible. The main difference to the 
previous study was that the Rome IV questionnaire does not contain 
a question specifically measuring frequent stools.
2.3.2 | Extraintestinal somatic symptoms
The	Patient	Health	Questionnaire	 (PHQ)‐1220 is a commonly used 
modification	 of	 the	 PHQ‐15,25 which is a validated measure as‐
sessing the severity of somatic symptoms, often referred to as 
“somatization.”	The	items	of	the	PHQ‐12	measure	twelve	common	
symptoms as a representation of non‐GI or extraintestinal somatic 
symptoms. Each question uses a scale from 0= “not bothered at 
all” to 2= “bothered a lot.” We used each question as a single‐item 
symptom registration in our mixture model. The questions measure 
the following symptoms: “back pain,” “pain in arms, legs or joints,” 
“pain or problems during sexual intercourse,” “headaches,” “chest 
pain,” “dizziness,” “fainting spells,” “feeling the heart pound or race 
(palpitations),” “shortness of breath,” “feeling tired or having low en‐
ergy (tiredness),” and “trouble sleeping.” The question for “menstrual 
cramps or other problems with the period” was not taken into the 
analysis due to gender relatedness.
2.3.3 | Psychological symptoms
To measure the severity of psychological distress, we used the Short 
Form (SF)‐8 score,21 a validated questionnaire commonly used in large‐
scale epidemiological studies. It measures the general health‐related 
quality	of	 life	 (QOL)	over	 the	past	month.	We	have	extracted	 three	
questions	with	Likert‐scale	answer	options	from	1	(not	at	all)	to	5	(ex‐
tremely) to represent psychological symptoms in our mixture model:
1. SF‐8‐social functioning asking for emotional/physical health:
During the past 4 weeks, how much did your physical 
health or emotional problems limit your usual social 
activities with family or friends?
SF‐8‐mental health asking for anxiety/depression/stress:
During the past 4 weeks, how much have you been 
bothered by emotional problems (such as feeling anx‐
ious, depressed or irritable)?
SF‐8‐emotional role asking for emotional problems:
During the past 4 weeks, how much did personal or 
emotional problems keep you from doing your usual 
work, school or other daily activities?
2.3.4 | Healthcare metrics
In addition to the above‐mentioned questions, several questions re‐
garding healthcare utilization and treatment were asked. Frequency 
of doctor visits (more than once a year or less), as well as doctor visits 
specifically due to GI problems, was enquired. Weekly use of GI‐spe‐
cific medications (laxatives, antidiarrheal, antiemetics, antacids, and 
antispasmodics) as well as analgesics (over the counter or prescrip‐
tion) and psychotropic medications (anxiolytics and antidepressants) 
was	assessed.	Additionally,	subjects	were	asked	about	any	history	of	
abdominal surgery (cholecystectomy, hysterectomy, appendectomy, 
bowel resection, as well as an open question regarding any abdomi‐
nal surgery).
2.4 | Statistical analysis
The statistical analysis was conducted using the R programming 
language	(version	3.3.2—“Sincere	Pumpkin	Patch“)26 for the mixture 
model analysis and parts of the multivariate comparisons as well as 
SPSS	(IBM	SPSS	Statistics	for	Windows,	version	24.0,	Armonk,	NY,	
USA;	2016)	for	univariate	and	parts	of	the	multivariate	comparisons.	
To conduct univariate comparison of symptom severity between the 
Rome III‐ and Rome IV‐positive groups, partially overlapping t‐test 
were performed using the “partiallyoverlapping” package of R.27,28
To stratify the Rome III‐ and Rome IV‐positive participants into 
subgroups, we conducted a mixture model analysis based on a 
Gaussian finite mixture model fitted by an expectation‐maximiza‐
tion algorithm, in line with the previous analyses conducted by our 
group on a clinical cohort.17 The mixture model analysis was per‐
formed using the”mclust” package of R29,30	version	5.3.
Gaussian mixture model analysis is a statistical strategy based 
on a probabilistic model,29,31 which stratifies a pooled population 
into naturally occurring clusters (latent classes, which we will refer 
to as subgroups in this paper). The basic assumption is that the given 
dataset is (a) a sample of a larger population and (b) a mix of observa‐
tions coming from different subgroups, with the aim of the analysis 
being to identify these subgroups by grouping together observations 
with similar patterns of variables. To achieve this, the modeling algo‐
rithm calculates a large number of subgroups and uses a fit statistic, 
the Bayesian information criterion,32 to determine the statistically 
optimal	subgroup	solution.	Mixture	model	analysis	was	conducted	
after log transformation of the dataset to account for nonparametric 
distribution.
The resulting subgroups were compared using analysis of vari‐
ance	 (ANOVA)	with	 step‐down	Bonferroni	 correction	 for	multiple	
testing where necessary. The respective symptom profiles were vi‐
sualized in radar plots based on Z‐scores (mean and standard devia‐
tion of the whole dataset set to zero).
The individual group profiles are termed according to their 
above‐average predominant symptoms (terms as, eg, “high comor‐
bidities” was used if the group average for extraintestinal somatic 
and psychological symptoms was above average, and the term “low 
comorbidities” if it was lower than average. Descriptors for individ‐
ual symptoms were used accordingly).
P‐values	of	<0.05	were	considered	significant.	Results	are	shown	
as mean values ± standard deviation (SD) for parametric tests or me‐
dian and interquartile range for nonparametric tests.
3  | RESULTS
3.1 | Descriptive data of the Rome III‐positive and 
Rome IV‐positive study cohorts
The Rome III‐positive cohort7	consisted	of	637	subjects.	More	than	
half	of	these	were	female,	and	the	mean	age	was	46	(±15.6)	years.	
More	than	half	of	the	Rome	III‐positive	cohort	was	characterized	




than once yearly as well as doctor visits specifically for GI prob‐
lems in both cohorts. GI‐specific medications and analgesics were 
used by around half of respondents, with a higher frequency in the 
Rome	IV	cohort.	Less	than	half	of	 the	respondents	used	psycho‐
tropic medication. Further details are shown in Table 1.
The Rome IV‐positive cohort showed a significantly higher mean 
severity or frequency of all these symptoms except pain severity 
and pain associated with meals compared to the Rome III‐positive 
cohort. Details regarding severity/frequency of all symptoms used 
for the mixture model analysis in both cohorts are shown in Table S1.
3.2 | Mixture model–based subgroups
3.2.1 | Rome III‐positive cohort
In this cohort, the best subgroup solution (maximal Bayesian infor‐
mation criterion) was seven subgroups (Figure S1). These seven sub‐
groups were characterized by specific symptom profiles (overview 
and	details	in	Figure	1,	schematic	overview	in	Figure	3A)	and	termed	
accordingly:
Two of the groups were characterized by above‐average scores 
for constipation‐related symptoms and two by above‐average scores 
for	 diarrhea‐related	 symptoms	 and	 pain.	 Additional	 discriminators	
between these pairs were below‐average or above‐average scores 
for extraintestinal somatic or psychological symptoms. These groups 
were	termed	constipation‐low	comorbidities	 (Figure	1A),	constipa‐
tion‐high comorbidities (Figure 1B), diarrhea‐pain‐low comorbid‐
ities (Figure 1C), and diarrhea‐pain‐high comorbidities (Figure 1D), 
respectively.
The remaining three groups were characterized by (a) mild se‐
verity of all measured symptoms (termed overall mild symptoms 
group, Figure 1E), (b) a mixed profile of above‐average scores for 
GI, extraintestinal somatic, and psychological symptoms (termed 
mixed‐high comorbidities, Figure 1F), and (c) above‐average scores 
for psychological symptoms and mild severity for all GI and extrain‐
testinal symptoms except tiredness (termed psychological symp‐
toms	 subgroup,	 Figure	 1G).	 A	 schematic	 overview	 is	 presented	 in	
Figure	4A.




In the Rome IV‐positive cohort, the maximal Bayesian information 
criterion was achieved for a five‐subgroup solution (Figure S2). Of 
these subgroups, one was characterized predominantly by constipa‐
tion‐related GI symptoms with additional above‐average psychologi‐
cal symptoms and was termed constipation‐predominant subgroup 
(Figure	2A).	Another	subgroup	was	characterized	predominantly	by	
pain and diarrhea‐related GI as well as psychological symptoms and 
termed diarrhea‐pain‐predominant subgroup (Figure 2B). The other 
three groups were characterized by a mix of symptoms and set apart 
by the severity of the respective symptom profiles: The mixed‐high 
psychological symptoms subgroup (Figure 2C) showed a mostly high 
symptom severity and especially high psychological symptoms but 
low intercourse‐related pain/problems, while the mixed‐moderate 
psychological symptoms group (Figure 2D) showed a similar profile 
but moderate psychological symptoms and high intercourse‐related 
pain/problems. The overall mild symptoms group showed below‐av‐
erage	scores	for	all	symptoms	(Figure	2E).	A	schematic	overview	is	
presented in Figure 3B.




In both cohorts, all subgroups showed a higher percentage of fe‐
males, with no statistically significant differences between the 
groups regarding gender distribution. The highest mean age was 
seen in the overall mild symptoms subgroups of both cohorts 
(P < 0.01 in both between‐group comparisons). IBS‐C and IBS‐D 
were present to a greater extent in the constipation‐ and diarrhea‐
pain‐predominant	subgroups,	but	not	limited	to	these,	while	IBS‐M	
and	IBS‐U	were	distributed	evenly	among	all	groups	except	the	diar‐
rhea‐pain‐predominant group of the Rome IV‐positive cohort which 
mostly contained IBS‐D (P < 0.01 in both between‐group compari‐
sons,	Figures	4	and	5).
In the high‐comorbidities groups of both cohorts, health care 
was utilized more frequently compared to the other groups (P < 0.01 
in both between‐group comparisons). In the Rome III‐positive co‐
hort, group differences were also significant regarding doctor visits 
specifically for GI problems (P < 0.01), which was more evenly dis‐
tributed in the Rome IV cohort. Groups with high non‐GI comorbid‐
ities reported more medication use in both cohorts (P < 0.01 in both 
between‐group comparisons). There were no statistically significant 
differences between the groups with regards to abdominal surger‐
ies.	Details	are	presented	in	Figures	4	and	5.
4  | DISCUSSION
In this study, the subgroups previously identified in a clinical Rome III 
IBS cohort could largely be reproduced in a population‐based sam‐
ple of individuals meeting Rome criteria for IBS. The previously seen 
symptom profiles were fully reproduced in the population‐based 







Demographics Age	(mean	±	SD) 46	±	15.6 44.5	±	14.6
‐ Count Percentage Count Percentage
Female 420 65.9% 217 63.6%
Male 217 34.1% 124 36.4%
Rome subtypes IBS‐C 106 16.6% 95 27.9%
IBS‐D 131 20.6% 117 34.3%
IBS‐M 383 60.1% 113 33.1%





481 75.5% 274 80.4%
Doctors visit due to GI 
problems
370 58.1% 227 66.6%
Medication	
taken at least 
once weekly
GI‐specific medication 351 55.1% 227 66.6%
Analgesics 342 53.7% 222 65.1%
Psychotropic	medicine 227 35.6% 150 44.0%
Any	of	the	above	
medication
492 77.2% 293 85.9%
Previous	
surgery
Abdominal	surgeries 242 38.0°% 153 44.9%
TA B L E  1   Demographic data and 
healthcare metrics in the Rome III‐positive 
and Rome IV‐positive cohort

symptom profiles were identified, as well as an additional seventh 
group. In the population‐based Rome IV IBS cohort, five subgroups 
with symptom profiles partly corresponding to the clinical paragon 
were identified, but with a preponderance of mixed symptom pro‐
files.	Like	the	subgroups	of	the	clinical	sample,	the	population‐based	
subgroups were characterized by a combination of GI symptoms 
with the additional distinction made by varying severity of non‐GI 
symptoms.	 Members	 of	 subgroups	 with	 high	 extraintestinal	 and	
psychological symptoms reported higher frequency of healthcare 
utilization and medication usage, but not more abdominal surgeries.
Due to the heterogeneity of IBS, there is a long‐standing history 
of stratification efforts (most importantly in Rome II‐IV criteria7,8,33), 
but these have focused solely on stool consistency. In a previous 
attempt to improve stratification of this complex disorder, our group 
created a classification approach17 that takes into account a compre‐
hensive set of GI, extraintestinal somatic, as well as psychological 
symptoms. To estimate the validity of this approach, we proposed 
three requirements to be tested34: reproducibility, potential dif‐
ferences in underlying pathophysiology, as well as whether group 
membership could be utilized as a predictor for treatment outcome. 
In the here presented study, we have, as a first step, explored the 
reproducibility of the subgroups.
We have first tested this reproducibility in a Rome III‐defined co‐
hort,7 as the clinical paragon17 was also based on a Rome III‐defined 
cohort.7 In this Rome III‐positive population‐based cohort, we suc‐
cessfully reproduced all groups and symptom associations previously 
described in the clinical patient cohort,17 with the addition of a group 
predominantly displaying psychological symptoms. These subgroups 
therefore seem to be present both in IBS patients and in a popula‐
tion‐based cohort fulfilling Rome III diagnostic criteria for IBS and 
have now been identified in cohorts from Sweden (clinical cohort17) 
as	well	as	the	USA,	UK,	and	Canada	(population‐based	cohort;	 the	
present study). This highlights a high level of reproducibility of these 
subgroups, supporting the validity of this subgrouping approach.
In light of the recent publication of the Rome IV criteria,8 we have 
also looked into subgroups and symptom associations in patients 
fulfilling these criteria and found similar but less distinct symptom 
associations. This is an outcome which may be expected given the 
change of diagnostic criteria and may be the result of a stricter se‐
lection of qualifying individuals due to the changes in symptom fre‐
quency thresholds utilized for diagnosis, as well as the removal of the 
symptom “discomfort.” These more selective criteria likely lead to a 
generally higher symptom severity in the Rome IV cohort (which was 
observed in this study, especially for non‐GI symptoms) and thus a 
more	 homogenous	 cohort.	As	 our	 statistical	 approach	 determines	
subgroups based on the relative severity of a profile of symptoms, 
overall high scores will lead to fewer, less distinct groups, just as 
observed.	 An	 additional	 noteworthy	 difference	 from	 the	 previous	
Rome III questionnaire is the removal of specific questions assess‐
ing frequent bowel movements, which may explain why three of the 
identified groups were characterized by a mix of GI symptoms rather 
than diarrhea or constipation.
Consistent with previous studies which showed extraintesti‐
nal symptoms to be of high relevance for the frequency of doctor 
visits,9‒11,13,14,16 our study observed more frequent healthcare uti‐
lization and medication usage in the groups showing above‐average 
extraintestinal somatic and psychological symptom severity. This 
further supports the importance of recognizing and considering 
these symptoms in clinical decision‐making to enable individualized 
treatment strategies for these patients, as previously suggested 
by use of a multidimensional clinical profiling strategy.11,35	Adding	
the relevant non‐GI symptoms to future IBS subtyping approaches 
may facilitate quicker and more comprehensive assessment of these 
symptoms and may therefore improve classification. While this 
seems relevant for the Rome III cohort, our results suggest that this 
may be even more important in the Rome IV cohort, where promi‐
nent non‐GI symptoms were generally observed.
Currently, IBS is viewed as a multifactorial disorder, with vari‐
ous pathophysiological mechanisms identified.36,37 However, not all 
of these mechanisms seem to be of relevance for all patients.36,37 
This hypothesis of multiple etiologies as opposed to multifacto‐
rial genesis has been gaining increasing support in the field of IBS 
research,9,37 and the symptom associations described here could 
potentially	 aid	 in	 identifying	 distinct	 underlying	 mechanisms.	 An	
important finding in this regard is the association of above‐average 
scores for diarrhea with above‐average scores for pain, which has 
consistently been observed in all cohorts.17 This recurrent pattern 
may suggest a common denominator between these symptoms and 
may therefore point toward a common etiology, a hypothesis that 
needs to be carefully evaluated in future studies. Our results also 
support the high importance of comprehensive clinical phenotyping 
to reduce heterogeneity and dissimilarity of patients. The potential 
presence of different endotypes needs to be accounted for when 
studying underlying mechanisms, and detailed phenotype‐based 
subgrouping such as suggested in this study may aid in identifying 
relevant mechanisms by enabling more quick and comprehensive 
screening for relevant symptoms.
This study is the first to utilize these advanced statistical methods 
to analyze latent structures for subgroups and symptom associations 
in a large numberof adult individuals from the general population 
and relating these symptom associations to healthcare usage. By 
utilizing an Internet‐based survey for data collection, we were able 
F I G U R E  1  A‐G,	Detailed	symptom	profiles	of	the	seven	subgroups	identified	in	the	Rome	III‐positive	cohort.	The	group	averages	are	
standardized and plotted in relation to the cohort average that is normalized to zero. Values above zero are thus above average, by which 
the group symptom profile can be determined. The average is marked with a dark‐red circle for easier determination of above‐ and below‐
average	severity	of	the	respective	symptoms.	In	each	panel,	the	respective	groups’	profile	is	highlighted	in	color	and	the	remaining	group	
profiles	are	kept	in	gray	in	the	background.	As	the	symptom	“Fainting	spells”	was	only	present	in	a	few	respondents,	it	was	removed	from	
this plot to improve comparability of the remaining symptoms
to generate a dataset that corresponded to the demographics of 
the general population in the respective countries. Built‐in qual‐
ity checks, such as automatic checks for missing or meaningless 
responses as well as checks to identify and exclude low‐quality 
respondents, were applied to ensure high‐quality data. This study 
design has, in recent years, become increasingly popular,38 and sev‐
eral recent studies focusing on GI symptoms with this type of meth‐
odology have been published.22,23,39‒41 This development has been 
F I G U R E  2  A‐E,	Detailed	symptom	profiles	of	the	five	subgroups	identified	in	the	Rome	IV‐positive	cohort.	The	group	averages	are	
standardized and plotted in relation to the cohort average that is normalized to zero. Values above zero are thus above average, by which 
the group symptom profile can be determined. The average is marked with a red circle for easier determination of above‐ and below‐average 
severity	of	the	respective	symptoms.	In	each	panel,	the	respective	groups’	profile	is	highlighted	in	color	and	the	remaining	group	profiles	are	
kept	in	gray	in	the	background.	As	the	symptom	“Fainting	spells”	was	only	present	in	a	few	respondents,	it	was	removed	from	this	plot	to	
improve comparability of the remaining symptoms
made possible by the near‐ubiquitous availability of Internet access 
in Western countries,42 minimizing the risk of recruitment bias due 
to Internet accessibility.
Nevertheless, some limitations need to be considered when in‐
terpreting the results:
It is possible that respondents of Internet surveys are different 
from those individuals not willing to participate in such surveys re‐
gardless of age, sex, etc, but there is little evidence of this to this 
date. Various previous studies focusing on several different health‐
care questions have shown that Internet surveys produce compa‐
rably reliable results as traditional survey strategies for assessing 
epidemiological measures.38 We therefore cannot find strong argu‐
ments contradicting the generalizability of our results due to poten‐
tial recruitment bias.
It is important to consider that this study was performed in 
Western countries, and global generalizability may be limited; 
therefore, further studies are needed to test for reproducibility in 
non‐Western countries. Nevertheless, the fact that we were able to 
reproduce our previously published subgroups in this large cohort 
provides a strong argument for the relevance and generalizability of 
these subgroups.
The present study had a cross‐sectional design, which needs 
to be considered. It is known that IBS symptoms fluctuate over 
time,43‒45 so it is unclear how stable the subgroup membership of 
an	 individual	 is.	Presumably,	 the	usage	of	a	comprehensive	set	of	
symptoms may aid in a higher longitudinal stability, but the sub‐
groups described here need to be subjected to further studies 
regarding longitudinal stability of group membership as well as pre‐
dictive abilities regarding underlying mechanisms and treatment 
outcome.
In conclusion, we have identified subgroups based on a compre‐
hensive set of IBS‐related symptoms in a population‐based study. 
F I G U R E  3  Schematic	overview	over	the	characteristics	of	the	latent	subgroups	present	in	A)	the	Rome	III‐	and	B)	Rome	IV‐positive	
cohort, respectively
These subgroups were defined by predominant GI symptoms and 
additionally by the respective severity of non‐GI symptoms, in 
line with previous findings in a clinical cohort.17 Subgroups with 
elevated non‐GI symptoms showed more frequent healthcare uti‐
lization and medication usage, suggesting that screening for these 
additional symptoms in IBS patients may aid clinicians in identi‐
fying those where gut‐directed therapeutic approaches may be 
sufficient as opposed to those that might benefit from therapies 
targeting extraintestinal somatic and psychological symptoms as 
well. Future studies are needed to further explore the reproducibil‐
ity of these subgroups in other cohorts and test the association of 
these specific symptom profiles to pathophysiological mechanisms 
as well as the suitability of these subgroups for predicting treat‐
ment outcome.
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